ME-CFS supplement evidence — what the trials actually support
Myalgic encephalomyelitis / chronic fatigue syndrome is a profoundly under-researched condition with a profoundly aggressive supplement market wrapped around it. The honest summary of the trial literature is that no supplement currently has the kind of evidence that warrants confident efficacy claims. Several have small studies with cautiously positive signals in specific symptom domains, and one or two are reasonable to try on a structured basis. This article tries to draw that line clearly.
The supplements with at least small RCT signal
CoQ10 (or ubiquinol) + NADH
200 mg ubiquinol + 20 mg NADH daily, with breakfast, for at least 8 weeks
The CoQ10 + NADH combination has the most consistent supportive trial signal in ME-CFS, with two small RCTs showing improvements in fatigue scores and PEM-related quality-of-life endpoints. Mechanistic rationale (mitochondrial bioenergetics deficits are a leading hypothesis) is plausible. Effect sizes are modest. Reasonable to try first if you want to add a single supplement intervention. Generally well tolerated.
Vitamin D3 (in deficient or borderline patients)
2,000–4,000 IU/day with a fatty meal; check 25-OH-D before and at 8 weeks
ME-CFS patients are more likely to have low 25-OH vitamin D than matched controls, partly explained by reduced sun exposure during illness. Repletion in deficient patients improves global symptom scores in small trials. Benefit in already-replete patients is unclear; do not just supplement without testing.
Magnesium (glycinate or malate)
300–400 mg elemental magnesium daily, evenings
An older small trial reported improvements in energy and mood with intramuscular magnesium injections in ME-CFS patients with low red-cell magnesium. Oral repletion at standard doses is reasonable as a foundation, but the dramatic original results have not been replicated with oral supplementation specifically in ME-CFS. Useful regardless for sleep and muscle pain.
Vitamin B12 (in deficient patients)
1,000–5,000 mcg methylcobalamin or hydroxycobalamin daily, sublingual or IM
Some practitioners report symptomatic improvement with high-dose B12 in ME-CFS, particularly in the POTS-overlap subgroup. Trial evidence is mixed and generally small. Always test serum B12 (and ideally methylmalonic acid) before supplementing high-dose long-term.
Honourable mentions — mechanism without trials
The compounds below have plausible mechanistic rationale but lack ME-CFS-specific RCT data. Reasonable to consider in an individualised plan with a clinician familiar with the condition; not yet ready for confident recommendation.
- D-ribose — a small open-label series in 2006 reported energy improvements at 5 g three times daily. Subsequent placebo-controlled work has not replicated cleanly, and effect on hard endpoints is unclear.
- L-carnitine (acetyl-L-carnitine or propionyl-L-carnitine) — small trials in fibromyalgia and ME-CFS suggest modest fatigue benefit. Effect size variable across studies.
- NAC (N-acetylcysteine) — antioxidant rationale, very thin direct ME-CFS evidence.
- Alpha-lipoic acid — antioxidant; some signal in fibromyalgia, less in ME-CFS specifically.
- Low-dose naltrexone — prescription, not a supplement, but the most-discussed off-label intervention in ME-CFS clinics. Small trials, plausible mechanism, requires a prescriber familiar with it.
What to skip — the marketed-but-unevidenced category
- "Mitochondrial complex" multi-ingredient products — typically combine sub-therapeutic doses of CoQ10, NADH, B-vitamins, and amino acids in one expensive capsule. Buying single ingredients at trial-validated doses costs less and works better.
- "Adrenal fatigue" complexes — adrenal fatigue is not a recognised ME-CFS subtype. The included adaptogens may help; the framing is misleading and the dosing is usually wrong.
- High-dose IV vitamin protocols — including the well-publicised "Myers cocktail" — have weak ME-CFS evidence, are expensive, and can carry meaningful infection and electrolyte risks.
- "Anti-inflammatory" turmeric / curcumin stacks at supraphysiological doses — modest anti-inflammatory effect in general use, no ME-CFS-specific signal, and can interact with anticoagulants.
- "Methylation support" complexes (high-dose methyl B-complexes for everyone) — can produce paradoxical worsening (the "over-methylation" pattern) in some users. If methylation is the target, do it carefully, ideally with MTHFR genotyping context.
The non-supplement layer that matters more
The intervention with the most consistent positive evidence in ME-CFS is structured pacing — operating within a personal energy envelope to avoid PEM. This is unfortunately invisible to drug trials and is not what the supplement industry sells, but it does more for most patients than any combination of supplements. Sleep optimisation, salt and fluid management for the POTS-overlap subgroup, and treatment of identified comorbidities (sleep apnoea, depression, low ferritin) all matter more than the supplement layer.
What to track
Useful patient-facing scales: the Chalder Fatigue Scale, the De Paul Symptom Questionnaire (PEM-specific), and a personal PEM-event count over weekly windows. Reassess any supplement at 8 to 12 weeks; stop if there's no clear effect on baseline symptoms.